Ri Liesner
Overview
Explore the profile of Ri Liesner including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
58
Citations
1788
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Alwan F, Vendramin C, Budde U, Liesner R, Taylor A, Thomas M, et al.
EJHaem
. 2022 Jul;
2(2):188-195.
PMID: 35845267
Despite clinical remission and normal platelet counts, congenital TTP (cTTP) is associated with non-overt symptoms. Prophylactic ADAMTS13 replacement therapy such as plasma infusion (PI) prevents acute episodes and improves symptomatology....
2.
Hart D, Alamelu J, Bhatnagar N, Biss T, Collins P, Hall G, et al.
Haemophilia
. 2021 Aug;
27(6):932-937.
PMID: 34403546
Introduction: In good risk patients (historic inhibitor peak < 200BU), the International Immune Tolerance Study demonstrated equal efficacy to induce tolerance between high (200iu/kg/day) and low dose (50iu/kg ×3 times/week)...
3.
Huang J, Liesner R, Austin S, Kavakli K, Akanezi C
Res Pract Thromb Haemost
. 2021 Jul;
5(5):e12550.
PMID: 34263102
Background: Coagadex is a high-purity plasma-derived factor X concentrate (pdFX) developed to treat hereditary factor X deficiency (FXD). Objective: Evaluate the efficacy and safety of pdFX administered to patients with...
4.
Peyvandi F, Auerswald G, Austin S, Liesner R, Kavakli K, Alvarez Roman M, et al.
Blood Rev
. 2021 May;
50:100833.
PMID: 34024682
Factor X deficiency is a rare coagulation disorder that can be hereditary or acquired. The typology and severity of the associated bleeding symptoms are highly heterogeneous, adding to the difficulties...
5.
Thorpe N, Harniess P, Main E, Hubert N, Rand S, Stephensen D, et al.
Pilot Feasibility Stud
. 2021 May;
7(1):105.
PMID: 33957997
Background: There is a lack of functional performance measures for children and young people with haemophilia (CYPwH) with associated control data from typically developing boys (TDB). The literature advocates development...
6.
Preijers T, Liesner R, Hazendonk H, Chowdary P, Driessens M, Hart D, et al.
Br J Clin Pharmacol
. 2021 Apr;
87(11):4408-4420.
PMID: 33884664
Aims: Population pharmacokinetic (PK) models are increasingly applied to perform individualized dosing of factor VIII (FVIII) concentrates in haemophilia A patients. To guarantee accurate performance of a population PK model...
7.
Liesner R, Andersson N, Frisk T, Santagostino E, Schulz M, Young L, et al.
Haemophilia
. 2020 Dec;
27(1):e60-e68.
PMID: 33277961
Introduction: European regulatory authorities request postmarketing safety and efficacy data for factor IX (FIX) products. Aim: Collect additional clinical data from routine nonacog alfa use in children aged <6 years...
8.
Andersson N, Wu R, Carcao M, Claeyssens-Donadel S, Kobelt R, Liesner R, et al.
Br J Haematol
. 2020 Jun;
190(2):e101-e104.
PMID: 32519345
No abstract available.
9.
van Velzen A, Eckhardt C, Peters M, Oldenburg J, Cnossen M, Liesner R, et al.
Br J Haematol
. 2020 Mar;
189(6):1182-1191.
PMID: 32201943
Inhibitor development is a major complication of treatment with factor VIII concentrates in nonsevere haemophilia A. It has been suggested that plasma-derived factor VIII (FVIII) concentrates elicit fewer inhibitors than...
10.
Male C, Andersson N, Rafowicz A, Liesner R, Kurnik K, Fischer K, et al.
Haematologica
. 2020 Jan;
106(1):123-129.
PMID: 31919092
The incidence of FIX inhibitors in severe hemophilia B (SHB) is not well defined. Frequencies of 3-5% have been reported but most studies to date were small, including patients with...